Jump to content

Opioidergic: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous edit
Content deleted Content added
VisualWikitext
Added short description
Tags: Mobile edit Mobile app edit Android app edit App suggested edit App description add
No edit summary
 
Line 1: Line 1:
{{Short description|Classification of chemicals that directly modulate opioid neuropeptide systems}}
{{Short description|Classification of chemicals that directly modulate opioid neuropeptide systems}}
[[File:Correlación estructural entre las encefalinas y la morfina.svg|thumb|260px|Structural correlation between [[met-enkephalin]], an opioid peptide, ''(left)'' and [[morphine]], an opiate drug, ''(right)'']]
[[File:Correlación estructural entre las encefalinas y la morfina.svg|thumb|260px|Structural correlation between [[met-enkephalin]], an opioid peptide, ''(left)'' and [[morphine]], an opiate drug, ''(right)'']]

{{Main article|Opioid}}
An '''opioidergic agent''' (or '''drug''') is a chemical which functions to directly modulate the [[opioid peptide|opioid neuropeptide]] systems (i.e., [[endorphin]], [[enkephalin]], [[dynorphin]], [[nociceptin]]) in the body or brain. Examples include [[opioid]] [[analgesic]]s such as [[morphine]] and [[opioid antagonist]]s such as [[naloxone]]. Opioidergics also comprise [[allosteric modulator]]s and [[enzyme]] affecting agents like [[enkephalinase inhibitor]]s.
An '''opioidergic agent''' (or '''drug''') is a chemical which directly or indirectly modulate the function of [[opioid receptor]]s. Opioidergics comprise [[opioid]]s, as well as [[allosteric modulator]]s and [[enzyme]] affecting agents like [[enkephalinase inhibitor]]s.


==Allosteric modulators==
==Allosteric modulators==
Line 8: Line 8:
* BMS-986121: μ-PAM<ref name="pmid23754417">{{cite journal |vauthors=Burford NT, Clark MJ, Wehrman TS, etal |title=Discovery of positive allosteric modulators and silent allosteric modulators of the μ-opioid receptor |journal=Proc. Natl. Acad. Sci. U.S.A. |volume=110 |issue=26 |pages=10830–5 |date=June 2013 |pmid=23754417 |pmc=3696790 |doi=10.1073/pnas.1300393110 |bibcode=2013PNAS..11010830B |doi-access=free }}</ref>
* BMS-986121: μ-PAM<ref name="pmid23754417">{{cite journal |vauthors=Burford NT, Clark MJ, Wehrman TS, etal |title=Discovery of positive allosteric modulators and silent allosteric modulators of the μ-opioid receptor |journal=Proc. Natl. Acad. Sci. U.S.A. |volume=110 |issue=26 |pages=10830–5 |date=June 2013 |pmid=23754417 |pmc=3696790 |doi=10.1073/pnas.1300393110 |bibcode=2013PNAS..11010830B |doi-access=free }}</ref>
* BMS-986122: μ-PAM<ref name="pmid23754417"/>
* BMS-986122: μ-PAM<ref name="pmid23754417"/>
* BPRMU191: confers agonistic properties to small-molecule morphinan antagonists<ref name="pmid39025070">{{cite journal |vauthors=Huang YH, Lin SY, Ou LC et al. |title=Discovery of a mu-opioid receptor modulator that in combination with morphinan antagonists induces analgesia |journal=Cell Chem Biol |volume=31 |issue=11 |pages=1885–1898.e10 |date=2024 |pmid=39025070 |doi=10.1016/j.chembiol.2024.06.013 |url=}}</ref>
* Ignavine<ref name="pmid27530869">{{cite journal |vauthors=Ohbuchi K, Miyagi C, Suzuki Y, Mizuhara Y, Mizuno K, Omiya Y, Yamamoto M, Warabi E, Sudo Y, Yokoyama A, Miyano K, Hirokawa T, Uezono Y |title=Ignavine: a novel allosteric modulator of the μ opioid receptor |journal=Sci Rep |volume=6 |pages=31748 |date=August 2016 |pmid=27530869 |pmc=4987652 |doi=10.1038/srep31748 |bibcode=2016NatSR...631748O }}</ref>
* Ignavine<ref name="pmid27530869">{{cite journal |vauthors=Ohbuchi K, Miyagi C, Suzuki Y, Mizuhara Y, Mizuno K, Omiya Y, Yamamoto M, Warabi E, Sudo Y, Yokoyama A, Miyano K, Hirokawa T, Uezono Y |title=Ignavine: a novel allosteric modulator of the μ opioid receptor |journal=Sci Rep |volume=6 |pages=31748 |date=August 2016 |pmid=27530869 |pmc=4987652 |doi=10.1038/srep31748 |bibcode=2016NatSR...631748O }}</ref>
* [[Oxytocin]]: μ-PAM<ref name="pmid29716811">{{cite journal |vauthors=Meguro Y, Miyano K, Hirayama S, et al |title=Neuropeptide oxytocin enhances μ opioid receptor signaling as a positive allosteric modulator |journal=J. Pharmacol. Sci. |volume=137 |issue=1 |pages=67–75 |date=May 2018 |pmid=29716811 |doi=10.1016/j.jphs.2018.04.002 |doi-access=free }}</ref>
* [[Oxytocin]]: μ-PAM<ref name="pmid29716811">{{cite journal |vauthors=Meguro Y, Miyano K, Hirayama S, et al |title=Neuropeptide oxytocin enhances μ opioid receptor signaling as a positive allosteric modulator |journal=J. Pharmacol. Sci. |volume=137 |issue=1 |pages=67–75 |date=May 2018 |pmid=29716811 |doi=10.1016/j.jphs.2018.04.002 |doi-access=free }}</ref>

Latest revision as of 16:39, 26 November 2024

Structural correlation between met-enkephalin, an opioid peptide, (left) and morphine, an opiate drug, (right)

An opioidergic agent (or drug) is a chemical which directly or indirectly modulate the function of opioid receptors. Opioidergics comprise opioids, as well as allosteric modulators and enzyme affecting agents like enkephalinase inhibitors.

Allosteric modulators

[edit]
BMS-986121

See also

[edit]

References

[edit]
  1. ^ a b Burford NT, Clark MJ, Wehrman TS, et al. (June 2013). "Discovery of positive allosteric modulators and silent allosteric modulators of the μ-opioid receptor". Proc. Natl. Acad. Sci. U.S.A. 110 (26): 10830–5. Bibcode:2013PNAS..11010830B. doi:10.1073/pnas.1300393110. PMC 3696790. PMID 23754417.
  2. ^ Huang YH, Lin SY, Ou LC, et al. (2024). "Discovery of a mu-opioid receptor modulator that in combination with morphinan antagonists induces analgesia". Cell Chem Biol. 31 (11): 1885–1898.e10. doi:10.1016/j.chembiol.2024.06.013. PMID 39025070.
  3. ^ Ohbuchi K, Miyagi C, Suzuki Y, Mizuhara Y, Mizuno K, Omiya Y, Yamamoto M, Warabi E, Sudo Y, Yokoyama A, Miyano K, Hirokawa T, Uezono Y (August 2016). "Ignavine: a novel allosteric modulator of the μ opioid receptor". Sci Rep. 6: 31748. Bibcode:2016NatSR...631748O. doi:10.1038/srep31748. PMC 4987652. PMID 27530869.
  4. ^ Meguro Y, Miyano K, Hirayama S, et al. (May 2018). "Neuropeptide oxytocin enhances μ opioid receptor signaling as a positive allosteric modulator". J. Pharmacol. Sci. 137 (1): 67–75. doi:10.1016/j.jphs.2018.04.002. PMID 29716811.
  5. ^ Burford NT, Livingston KE, Canals M, Ryan MR, Budenholzer LM, Han Y, Shang Y, Herbst JJ, O'Connell J, Banks M, Zhang L, Filizola M, Bassoni DL, Wehrman TS, Christopoulos A, Traynor JR, Gerritz SW, Alt A (2015). "Discovery, Synthesis, and Molecular Pharmacology of Selective Positive Allosteric Modulators of the δ-Opioid Receptor". J. Med. Chem. 58 (10): 4220–9. doi:10.1021/acs.jmedchem.5b00007. PMC 4703104. PMID 25901762.
  6. ^ a b Kathmann M, Flau K, Redmer A, Tränkle C, Schlicker E (February 2006). "Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors". Naunyn-Schmiedeberg's Arch. Pharmacol. 372 (5): 354–61. doi:10.1007/s00210-006-0033-x. PMID 16489449. S2CID 4877869.
  7. ^ Shang Y, LeRouzic V, Schneider S, Bisignano P, Pasternak GW, Filizola M (2014). "Mechanistic insights into the allosteric modulation of opioid receptors by sodium ions". Biochemistry. 53 (31): 5140–9. doi:10.1021/bi5006915. PMC 4131901. PMID 25073009.


Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Opioidergic&oldid=1259704171"